AstraZeneca commits an additional $100 million to venture capital arm MedImmune Ventures
Publication date: 28 November 2011
Author: AstraZeneca
Tagged with: AstraZeneca, MedImmune Ventures, Ron Laufer, Simon Lowth
AstraZeneca today announced that it has committed an additional $100 million to its venture capital arm, MedImmune Ventures, increasing the total capital under management to $400 million. MedImmune Ventures is an evergreen venture capital fund that focuses on equity investments in private companies in the areas of biopharmaceuticals, medical and healthcare technology.
“With the additional funding from AstraZeneca, we look forward to expanding our investment activities globally and across therapy areas. We believe that in the current financial environment, there is a growing role for corporate venture capital funds such as MedImmune Ventures,” said Ron Laufer, Senior Managing Director, MedImmune Ventures.
Simon Lowth, Chief Financial Officer, AstraZeneca said: “We continue to support MedImmune Ventures strategy that combines commitment to advance science and technology in the life science industry while generating financial returns expected of venture capital funds.”
Additionally, AstraZeneca also announced that MedImmune Ventures has co-led the second round of financing for NeuProtect Pty Ltd, an Australian life science company specialised in the reduction of cardiac remodelling post myocardial infarction. Ron Laufer said: “We are delighted to co-lead with Starfish Ventures a new round of financing for NeuProtect Pty Ltd, our first investment in an Australian company.”
Advertisement:
Email newsletter
If you enjoyed this article sign-up to receive our bi-weekly email newsletter:
Latest news
- Novartis NVA237 Phase III data showed rapid, sustained improvement in lung function and symptom relief over one year in COPD patients (17 May 2012)
- Amgen’s BiTE® Antibody Blinatumomab achieved high rate of complete response in adult patients with relapsed or refractory acute lymphoblastic leukemia (16 May 2012)
- GlaxoSmithKline completes transaction to increase its ownership in Theravance (16 May 2012)
- Catalent announces winners of Global Academic Competition for Life Science Leaders of Tomorrow (16 May 2012)
- Roche will report new data on important progress for people with advanced cancers at ASCO 2012 (16 May 2012)
In-depth focus:
Mass Spectrometry
This free to view Mass Spectrometry in-depth focus is sponsored by Waters, Bruker, Protea and Dr. Hochmuth and contains the following articles:
- Mass spectrometry in drug discovery - Proteomics, small molecules and metablomics
- Quantification of membrane drug transporters and application in drug discovery and development
- Anthony Bristow, AstraZeneca, poses the questions for our Mass Spectrometry Leaders Roundtable
Company directory
ABB Analytical Measurements | Almac | B&W Tek, Inc. | BASF | BD Diagnostics | Bio-Optronics, Inc. | bioMérieux | BioTek Instruments, Inc. | Bruker Optics | CAMO Software AS | Catalent Pharma Solutions | Chemspec Europe Ltd | CI Precision | Cisbio Bioassays | EMD Millipore | GE Analytical Instruments | Gerresheimer Group | HACH LANGE GMBH | HORIBA Scientific | I Holland Limited | Lonza | Merck Millipore | Pall Life Sciences | Patheon Inc | Phenomenex | Porvair Sciences Ltd | Randox Pharma Services | Rapid Micro Biosystems | Realia | Roche | rommelag® | Umetrics |
Login to access exclusive content